Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.33 |
| ▸ | PLK4 | O00444 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | FES | P07332 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | ROS1 | P08922 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488969 | 1.00 | MAPK1 (1.00) | MAPK1CHEK1KDRCDK5AURKB | |
| SCHEMBL12657766 | 0.80 | MAPK1 (0.67) | MAPK1CHEK1BRD4 | |
| SCHEMBL2377045 | 0.77 | MAPK1 (0.62) | MAPK1KDRCDK5AURKBCLK4 | |
| SCHEMBL14616216 | 0.77 | MAPK1 (0.62) | MAPK1CHEK1JAK2SYKJAK3 | |
| SCHEMBL30258999 | 0.77 | MAPK1 (0.62) | MAPK1CHEK1BRD4 | |
| SCHEMBL25257114 | 0.77 | MAPK1 (0.62) | MAPK1KDRCDK5AURKBCLK4 | |
| SCHEMBL14331928 | 0.77 | MAPK1 (0.62) | MAPK1KDRCDK5AURKBCLK4 | |
| SCHEMBL2378181 | 0.77 | MAPK1 (0.62) | MAPK1KDRCDK5AURKBCLK4 | |
| SCHEMBL21821096 | 0.77 | MAPK1 (0.62) | MAPK1CHEK1BRD4 | |
| SCHEMBL30491243 | 0.77 | MAPK1 (0.62) | MAPK1KDRCDK5AURKBCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102627646-A | Preparation method of 3-iodo-5-bromo-4, 7-diazaindole | STONE LAKE PHARMA TECH CO LTD | 2012-08-08 | — | — | CN | claimed |
| EP-4698531-A1 | PYRROLOPYRAZINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2026-02-25 | — | — | EP | disclosed |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-11-04 | — | — | US | disclosed |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | NIMBUS CLOTHO, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | PFIZER INC (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2024218235-A1 | PYRROLOPYRAZINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2024-10-24 | — | — | WO | disclosed |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | PFIZER INC. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-118344342-A | Substituted polyaromatic ring derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | BEIGENE, LTD. (KY) | 2024-07-11 | — | — | US | disclosed |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2024-06-06 | — | — | US | disclosed |
| US-7452993-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452993-B2 | morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia | SGX PHARMACEUTICALS, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124850-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| EP-1778687-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | STRUCTURAL GENOMIX, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035898-A1 | Fused ring heterocycle kinase modulators | MAP3K20, TTK, MAP3K19 | MAPK1 319/4885CHEK1 237/4885KDR 490/4885 |
| US-12077533-B2 | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | ACR, PKD2, PGA5 | MAPK1 2289/4885CHEK1 718/4885KDR 3206/4885 |
| US-20070287711-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, TTK, MAP3K19 | MAPK1 319/4885CHEK1 237/4885KDR 490/4885 |
| US-20250134869-A1 | Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides | JAK2, JAK3, JAK1 | MAPK1 232/4885CHEK1 339/4885KDR 1012/4885 |
| US-20240228497-A1 | Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof | HIPK1, MDM2, JMJD7 | MAPK1 2514/4885CHEK1 621/4885KDR 2144/4885 |
| US-12331046-B2 | CTPS1 inhibitors and uses thereof | CTPS1, CTPS2, ECHS1 | MAPK1 4157/4885CHEK1 658/4885KDR 4219/4885 |
| US-20240182465-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE1, WEE2, HASPIN | MAPK1 300/4885CHEK1 1335/4885KDR 3959/4885 |
| US-12459958-B2 | Tricyclic compounds as HPK1 inhibitor and the use thereof | ULK1, SBK1, PHKG1 | MAPK1 363/4885CHEK1 309/4885KDR 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.